| COVANCE ELECTS KATHLEEN G. MURRAY TO BOARD OF DIRECTORS |
|
Princeton, New Jersey, July 14, 1998 — Covance Inc. [NYSE: CVD] today announced that it elected Kathleen G. Murray to its Board of Directors effective June 9, 1998. Ms. Murray is the Executive Vice President and Chief Operating Officer (COO) of Northwestern Memorial Corporation in Chicago, IL. Northwestern Memorial is a premier academic medical center with revenues of over $600M and a member of Northwestern Healthcare Network, the largest healthcare system in the Chicago area.
Ms. Murray has more than 25 years of experience in the healthcare industry. She joined Northwestern Memorial in 1986 and is recognized for her leadership in the development of clinical centers of excellence, her financial management skills, and her commitment to excellence in patient care. Ms. Murray is active in the American Hospital Association, where she currently serves as Chair of the Governing Council for Metropolitan Hospitals. She also serves on the board of the Illinois Hospital and Health Systems Association, Dominican University, and The Economic Club of Chicago. Ms. Murray participates in a number of other civic and community activities, as well.
"Kathleen's expertise in successfully running a world-class medical institution and her insight into patient issues and standards of care will strengthen Covance and our ability to enhance the clinical drug development process for our pharmaceutical clients and the patients they serve", said Chris A. Kuebler, Covance Chairman and Chief Executive Officer.
Northwestern Memorial is consistently ranked among the top hospitals and academic medical centers nationwide and is recognized for its centers of excellence in cardiovascular, cancer, neuroscience, geriatrics, and women's health. The development of these programs has led to breakthrough treatments and the realization of many medical firsts at Northwestern.
Covance, with headquarters in Princeton, NJ, is one of the world's largest and most comprehensive contract drug development service companies, with 1997 revenues of approximately $590 million, operations currently in 17 countries, and more than 6,300 employees worldwide. Covance's purpose is to lead advancements in drug development through science, service, and shaping solutions. |
|
|
